Population pharmacokinetics of oseltamivir in non-pregnant and pregnant women

British Journal of Clinical Pharmacology

Volumn 80, Issue 5, 2015, Pages 1042-1050

  Pillai, Venkateswaran C ^a   Han, Kelong ^b   Beigi, Richard H ^c   Hankins, Gary D ^d   Clark, Shannon ^d   Hebert, Mary F ^e   Easterling, Thomas R ^e   Zajicek, Anne ^f   Ren, Zhaoxia ^f   Caritis, Steve N ^c   Venkataramanan, Raman ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b GENENTECH INC   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

oseltamivir; population pharmacokinetics; pregnancy

Indexed keywords

OSELTAMIVIR; 4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; ANTIVIRUS AGENT;

ABSORPTION RATE CONSTANT; ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; FEMALE; HUMAN; INFLUENZA; METABOLITE; MULTICENTER STUDY; POPULATION; PREGNANCY; PREGNANT WOMAN; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SIMULATION; STEADY STATE; VOLUME OF DISTRIBUTION; ADOLESCENT; ANALOGS AND DERIVATIVES; BIOLOGICAL MODEL; BLOOD; CLINICAL TRIAL; COMPUTER SIMULATION; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; COMPUTER SIMULATION; FEMALE; HUMANS; MIDDLE AGED; MODELS, BIOLOGICAL; OSELTAMIVIR; PREGNANCY; YOUNG ADULT;

EID: 84946499300     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12691     Document Type: Article

References (29)

1. Freeman DW, Barno A,. Deaths from Asian influenza associated with pregnancy. Am J Obstet Gynecol 1959; 78: 1172-5.
2. Mosby LG, Rasmussen SA, Jamieson DJ,. 2009 pandemic influenza A (H1N1) in pregnancy: a systematic review of the literature. Am J Obstet Gynecol 2011; 205: 10-8.
3. Centers for Disease Control and Prevention. Available at http://www.cdc.gov/flu/protect/vaccine/pregnant.htm (last accessed 2014). In, Atlanta, GA, 2014.
4. Cervantes-Gonzalez M, Launay O,. Pandemic influenza A (H1N1) in pregnant women: impact of early diagnosis and antiviral treatment. Expert Rev Anti Infect Ther 2010; 8: 981-4.
5. Fiore AE, Fry A, Shay D, Gubareva L, Bresee JS, Uyeki TM,. Antiviral agents for the treatment and chemoprophylaxis of influenza - - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recommendations and reports: morbidity and mortality weekly report and reports / Centers for Disease Control 2011; 60: 1-24.
6. He G, Massarella J, Ward P,. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet 1999; 37: 471-84.
7. Gubareva LV, Kaiser L, Hayden FG,. Influenza virus neuraminidase inhibitors. Lancet 2000; 355: 827-35.
8. Beigi RH, Han K, Venkataramanan R, Hankins GD, Clark S, Hebert MF, Easterling T, Zajicek A, Ren Z, Mattison DR, Caritis SN,. Pharmacokinetics of oseltamivir among pregnant and nonpregnant women. Am J Obstet Gynecol 2011; 204: S84-8.
9. Tamiflu Product Monograph. Available at https://www.healthunit.com/uploads/tamiflu-product-monograph.pdf. (last accessed 2013) Hoffmann-La Roche Limited, 2013.
10. Loebstein R, Lalkin A, Koren G,. Pharmacokinetic changes during pregnancy and their clinical relevance. Clin Pharmacokinet 1997; 33: 328-43.
11. Canini L, Conway JM, Perelson AS, Carrat F,. Impact of different oseltamivir regimens on treating influenza A virus infection and resistance emergence: insights from a modelling study. PLoS Comput Biol 2014; 10: e1003568.
12. Kamal MA, Acosta EP, Kimberlin DW, Gibiansky L, Jester P, Niranjan V, Rath B, Clinch B, Sanchez PJ, Ampofo K, Whitley R, Rayner CR,. The Posology of Oseltamivir in Infants With Influenza Infection Using a Population Pharmacokinetic Approach. Clin Pharmacol Ther 2014; 96: 380-9.
13. Kamal MA, Van Wart SA, Rayner CR, Subramoney V, Reynolds DK, Bulik CC, Smith PF, Bhavnani SM, Ambrose PG, Forrest A,. Population pharmacokinetics of oseltamivir: pediatrics through geriatrics. Antimicrob Agents Chemother 2013; 57: 3470-7.
14. Pai MP, Lodise TP, Jr., Oseltamivir and oseltamivir carboxylate pharmacokinetics in obese adults: dose modification for weight is not necessary. Antimicrob Agents Chemother 2011; 55: 5640-5.
15. Rayner CR, Bulik CC, Kamal MA, Reynolds DK, Toovey S, Hammel JP, Smith PF, Bhavnani SM, Van Wart SA, Ambrose PG, Forrest A,. Pharmacokinetic-pharmacodynamic determinants of oseltamivir efficacy using data from phase 2 inoculation studies. Antimicrob Agents Chemother 2013; 57: 3478-87.
16. Rayner CR, Chanu P, Gieschke R, Boak LM, Jonsson EN,. Population pharmacokinetics of oseltamivir when coadministered with probenecid. J Clin Pharmacol 2008; 48: 935-47.
17. Standing JF, Nika A, Tsagris V, Kapetanakis I, Maltezou HC, Kafetzis DA, Tsolia MN,. Oseltamivir pharmacokinetics and clinical experience in neonates and infants during an outbreak of H1N1 influenza A virus infection in a neonatal intensive care unit. Antimicrob Agents Chemother 2012; 56: 3833-40.
18. Davies BE,. Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations. J Antimicrob Chemother 2010; 65 Suppl 2: ii5-ii10.
19. Wiltshire H, Wiltshire B, Citron A, Clarke T, Serpe C, Gray D, Herron W,. Development of a high-performance liquid chromatographic-mass spectrometric assay for the specific and sensitive quantification of Ro 64-0802, an anti-influenza drug, and its pro-drug, oseltamivir, in human and animal plasma and urine. J Chromatogr B Biomed Sci Appl 2000; 745: 373-88.
20. Massarella JW, He GZ, Dorr A, Nieforth K, Ward P, Brown A,. The pharmacokinetics and tolerability of the oral neuraminidase inhibitor oseltamivir (Ro 64-0796/GS4104) in healthy adult and elderly volunteers. J Clin Pharmacol 2000; 40: 836-43.
21. Food and Drug Administration. Available at http://www.fda.gov/downloads/drugs/drugsafety/informationbydrugclass/ucm147992.pdf. 2008.
22. Beal S, Sheiner LB, Boeckmann A, Bauer RJ,. NONMEM user's guides (1989-2009). Ellicott City, MD: Icon Development Solutions, 2009.
23. Cardenas I, Means RE, Aldo P, Koga K, Lang SM, Booth CJ, Manzur A, Oyarzun E, Romero R, Mor G,. Viral infection of the placenta leads to fetal inflammation and sensitization to bacterial products predisposing to preterm labor. J Immunol (Baltimore, Md: 1950) 2010; 185: 1248-57.
24. Velasquez J, Velez G, Zuleta J, Franco F, Gomez J,. H1N1 influenza pandemic and maternal mortality in Antioquia, Colombia. Int J Gynaecol Obstet 2011; 115: 144-7.
25. Dede FS, Celen S, Bilgin S, Ure G, Ozcan AO, Buzgan T, Kose R,. Maternal deaths associated with H1N1 influenza virus infection in Turkey: a whole-of-population report. BJOG 2011; 118: 1216-22.
26. Influenza vaccination coverage among pregnant women - United States, 2012-13 influenza season. MMWR Morb Mortal Wkly Rep 2013; 62: 787-92.
27. Aarons L, Karlsson MO, Mentre F, Rombout F, Steimer JL, van Peer A,. Role of modelling and simulation in Phase I drug development. Eur J Pharm Sci 2001; 13: 115-22.
28. Davison JM, Dunlop W,. Renal hemodynamics and tubular function normal human pregnancy. Kidney Int 1980; 18: 152-61.
29. Greer LG, Leff RD, Rogers VL, Roberts SW, McCracken GH, Jr., Wendel GD, Jr., Sheffield JS,. Pharmacokinetics of oseltamivir according to trimester of pregnancy. Am J Obstet Gynecol 2011; 204: S89-93.